2020
Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry
Kelly CR, Yen EF, Grinspan AM, Kahn SA, Atreja A, Lewis JD, Moore TA, Rubin DT, Kim AM, Serra S, Nersesova Y, Fredell L, Hunsicker D, McDonald D, Knight R, Allegretti JR, Pekow J, Absah I, Hsu R, Vincent J, Khanna S, Tangen L, Crawford CV, Mattar MC, Chen LA, Fischer M, Arsenescu RI, Feuerstadt P, Goldstein J, Kerman D, Ehrlich AC, Wu GD, Laine L. Fecal Microbiota Transplantation Is Highly Effective in Real-World Practice: Initial Results From the FMT National Registry. Gastroenterology 2020, 160: 183-192.e3. PMID: 33011173, PMCID: PMC8034505, DOI: 10.1053/j.gastro.2020.09.038.Peer-Reviewed Original ResearchConceptsClostridioides difficile infectionMicrobiota transplantationSafety profileNational registryProspective real-world studyFull safety profileProspective safety dataBaseline patient characteristicsInflammatory bowel diseaseIrritable bowel syndromeFecal microbiota transplantationLong-term safety outcomesGood safety profileReal-world studyAbdominal painBowel syndromePatient characteristicsReal-world practiceBowel diseaseCDI recurrenceDifficile infectionSafety dataSafety outcomesEffectiveness outcomesSevere symptoms
2017
Optimal Timing of Endoscopic Retrograde Cholangiopancreatography in Acute Cholangitis
Hou LA, Laine L, Motamedi N, Sahakian A, Lane C, Buxbaum J. Optimal Timing of Endoscopic Retrograde Cholangiopancreatography in Acute Cholangitis. Journal Of Clinical Gastroenterology 2017, 51: 534-538. PMID: 27875357, DOI: 10.1097/mcg.0000000000000763.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAdolescentAdultAgedAged, 80 and overCholangiopancreatography, Endoscopic RetrogradeCholangitisFemaleHospitalizationHumansIntensive Care UnitsIntubation, IntratrachealLength of StayMaleMiddle AgedMultivariate AnalysisProspective StudiesTime FactorsTreatment OutcomeYoung AdultConceptsEndoscopic retrograde cholangiopancreatographyIntensive care unit admissionCare unit admissionLength of hospitalizationAcute cholangitisUnit admissionRetrograde cholangiopancreatographyFrequent intensive care unit admissionOptimal timingAdditional adverse outcomesCases of cholangitisProcedural adverse eventsDays of presentationVasopressor requirementVasopressor supportBiliary decompressionHospital stayVasopressor useSecondary outcomesAdverse eventsAntibiotic therapyPrimary outcomeEndotracheal intubationAdverse outcomesEmergency department
2015
Treatment of Refractory Gastrointestinal Strictures With Mitomycin C
Rustagi T, Aslanian HR, Laine L. Treatment of Refractory Gastrointestinal Strictures With Mitomycin C. Journal Of Clinical Gastroenterology 2015, 49: 837-847. PMID: 25626632, DOI: 10.1097/mcg.0000000000000295.Peer-Reviewed Original ResearchConceptsMitomycin C applicationMitomycin CGastrointestinal stricturesSystematic reviewLimited therapeutic interventionsAdditional randomized trialsLarge prospective studiesDifficult management problemSearch of MEDLINEBenign gastrointestinal stricturesTitles/abstractsCutaneous sclerosisAdverse eventsPartial responseComplete responseCaustic injuryRandomized trialsRefractory stricturesEsophageal strictureProspective studyEmbase databasesCommon siteEffective therapyInclusion criteriaOptimal dose
2010
Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate‐to‐severe erosive oesophagitis – the results of two double‐blind studies
Laine L, Katz PO, Johnson DA, Ibegbu I, Goldstein MJ, Chou C, Rossiter G, Lu Y. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate‐to‐severe erosive oesophagitis – the results of two double‐blind studies. Alimentary Pharmacology & Therapeutics 2010, 33: 203-212. PMID: 21114792, DOI: 10.1111/j.1365-2036.2010.04516.x.Peer-Reviewed Original ResearchConceptsHeartburn resolutionErosive oesophagitisExtended releaseLA grade CSevere erosive oesophagitisDouble-blind trialDouble-blind studyPossibility of benefitCurrent PPIsD oesophagitisSevere oesophagitisGERD patientsSecondary endpointsPrimary endpointSymptomatic resolutionAcid suppressionSubgroup analysisDrug exposureClinical trialsOesophagitisGrade DGrade CFurther evaluationEsomeprazoleAcid inhibition
2008
Foreign-body ingestion: characteristics and outcomes in a lower socioeconomic population with predominantly intentional ingestion
Palta R, Sahota A, Bemarki A, Salama P, Simpson N, Laine L. Foreign-body ingestion: characteristics and outcomes in a lower socioeconomic population with predominantly intentional ingestion. Gastrointestinal Endoscopy 2008, 69: 426-433. PMID: 19019363, DOI: 10.1016/j.gie.2008.05.072.Peer-Reviewed Original ResearchConceptsForeign body ingestionUrban county hospitalIntentional ingestionEndoscopic extractionCounty HospitalPsychiatric patientsLow socioeconomic status populationRetrospective case seriesLow socioeconomic populationOverall success rateCase seriesRetrospective reviewEndoscopic managementIngestion casesMedical recordsPrior ingestionAccidental ingestionPatientsSocioeconomic populationsSurgeryStatus populationIngestionPerforationSuccess rateHospitalTegaserod Treatment for Dysmotility-Like Functional Dyspepsia: Results of Two Randomized, Controlled Trials
Vakil N, Laine L, Talley NJ, Zakko SF, Tack J, Chey WD, Kralstein J, Earnest DL, Ligozio G, Cohard-Radice M. Tegaserod Treatment for Dysmotility-Like Functional Dyspepsia: Results of Two Randomized, Controlled Trials. The American Journal Of Gastroenterology 2008, 103: ajg2008383. PMID: 18616658, DOI: 10.1111/j.1572-0241.2008.01953.x.Peer-Reviewed Original ResearchConceptsDysmotility-like functional dyspepsiaFunctional dyspepsiaSatisfactory symptom reliefTegaserod treatmentSymptom reliefDaily severity scoresPlacebo-controlled trialSevere baseline symptomsHelicobacter pylori statusTrial 2Trial 1Percentage of daysEarly satietyIdentical multicenterPostprandial fullnessStudy discontinuationAbdominal discomfortControlled TrialsMedication usePylori statusSeverity scoreReceptor agonistBaseline symptomsTegaserodClinical implications
1999
A multicentre evaluation of the laser assisted ratio analyser (LARA): a novel device for measurement of 13CO2 in the 13C‐urea breath test for the detection of Helicobacter pylori infection
Cave DR, van Zanten S, Carter E, Halpern EF, Klein S, Prather C, Stolte M, Laine L. A multicentre evaluation of the laser assisted ratio analyser (LARA): a novel device for measurement of 13CO2 in the 13C‐urea breath test for the detection of Helicobacter pylori infection. Alimentary Pharmacology & Therapeutics 1999, 13: 747-752. PMID: 10383503, DOI: 10.1046/j.1365-2036.1999.00534.x.Peer-Reviewed Original Research
1995
Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double‐blind trial
LAINE L, COMINELLI F, SLOANE R, CASINI‐RAGGI V, MARIN‐SORENSEN M, WEINSTEIN WM. Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double‐blind trial. Alimentary Pharmacology & Therapeutics 1995, 9: 127-135. PMID: 7605852, DOI: 10.1111/j.1365-2036.1995.tb00361.x.Peer-Reviewed Original ResearchConceptsNonsteroidal anti-inflammatory drugsH. pylori infectionNSAID ingestionProstaglandin E2 productionHistological injuryWeek 1H. pyloriGastroduodenal injuryPylori infectionNegative subjectsE2 productionWeek 4Prostaglandin productionH. pylori-associated gastritisDouble-blind trialNormal baseline endoscopyAnti-inflammatory drugsBaseline endoscopyChemical gastritisGastroduodenal damagePlacebo b.Gastrointestinal injuryNSAID useGastric histologyNSAID group